Company intelligence / Profile preview

AAZPIRE

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Aazpire Therapeutics is a clinical-stage biotechnology company focused on developing next-generation small molecule inhibitors for the treatment of cancer. The company's primary focus is on the adenosine pathway, specifically targeting the A2A and A2B receptors to overcome immunosuppression in the tumor microenvironment. Led by experienced industry veterans, Aazpire aims to improve outcomes for patients with solid tumors through highly selective and potent therapeutic candidates. Their lead programs are designed to be used both as monotherapies and in combination with other immuno-oncology agents.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on AAZPIRE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAZPIRE.

Explore the full profile